INTERNATIONAL RESEARCH & OPINION Better care in Alzheimer's disease? The number of managed-care plans for the treatment of patients with Alzheimer's disease (AD) is likely to increase in the US, according to a new Datamonitor report. The report states that the care for patients with AD in the US remains poor. Therefore, new initiatives, involving health maintenance organisations, Medicare and pharmaceutical companies, have been launched in an attempt to improve the quality of care in the managed- care setting. Improvements in the management of AD may also generate cost savings, suggests Datanwnitor. Recent and future drugs used in the treatment of patients with AD will be supported at launch by disease management (DM) programmes that will be introduced simultaneously. Such DM progranunes have already been developed and implemented in line with the marketing of some medications: e.g. 'The Family Care System' was developed by Warner-Lambert in association with tacrine. and TriAD, although not a product-specific programme, was launched by Eisai and Pfizer in association with donepezil. Datarnonitor. Pharmaceutical companies, HMOs and disease associations take new initiatives to improve the management of Alzheimer's disease. Media Release: [5 pages], 17 Nov 1997 800629019 1173-SSOMl710140-000111$01.000 Adlslnternatlonal Limited 1997. All rights ..... rved PharmacoEconomics & Outcomes News 29 Nov 1997 No. 140 II INTERNATIONAL RESEARCH & OPINION Better care in Alzheimer's disease? The number of managed-care plans for the treatment of patients with Alzheimer's disease (AD) is likely to increase in the US, according to a new Datamonitor report. The report states that the care for patients with AD in the US remains poor. Therefore, new initiatives, involving health maintenance organisations, Medicare and pharmaceutical companies, have been launched in an attempt to improve the quality of care in the managed- care setting. Improvements in the management of AD may also generate cost savings, suggests Datanwnitor. Recent and future drugs used in the treatment of patients with AD will be supported at launch by disease management (DM) programmes that will be introduced simultaneously. Such DM progranunes have already been developed and implemented in line with the marketing of some medications: e.g. 'The Family Care System' was developed by Warner-Lambert in association with tacrine, and TriAD, although not a product-specific programme, was launched by Eisai and Pfizer in association with donepezil. Datarnonitor. Pharmaceutical companies, HMOs and disease associations take new initiatives to improve the management of Alzheimer's disease. Media Release: [5 pages], 17 Nov 1997 lIOO629Ol9 II 1173-55Q319710140-000111$01.oo0 Adlsinternationaillmlted 1997. All rlghts .....rved PharmacoEconomics & Outcomes News 29 Nov 1997 No. 140

Better care in Alzheimer’s disease?

Download PDF Report

Upload
vannhu
View
214
Download
2

Embed Size (px)

Citation preview

Page 1: Better care in Alzheimer’s disease?

INTERNATIONAL RESEARCH & OPINION

Better care in Alzheimer's disease? The number of managed-care plans for the treatment

of patients with Alzheimer's disease (AD) is likely to increase in the US, according to a new Datamonitor report.

The report states that the care for patients with AD in the US remains poor. Therefore, new initiatives, involving health maintenance organisations, Medicare and pharmaceutical companies, have been launched in an attempt to improve the quality of care in the managedcare setting. Improvements in the management of AD may also generate cost savings, suggests Datanwnitor.

Recent and future drugs used in the treatment of patients with AD will be supported at launch by disease management (DM) programmes that will be introduced simultaneously. Such DM progranunes have already been developed and implemented in line with the marketing of some medications: e.g. 'The Family Care System' was developed by Warner-Lambert in association with tacrine. and TriAD, although not a product-specific programme, was launched by Eisai and Pfizer in association with donepezil. Datarnonitor. Pharmaceutical companies, HMOs and disease associations take new initiatives to improve the management of Alzheimer's disease. Media Release: [5 pages], 17 Nov 1997 800629019

1173-SSOMl710140-000111$01.000 Adlslnternatlonal Limited 1997. All rights ..... rved PharmacoEconomics & Outcomes News 29 Nov 1997 No. 140

II INTERNATIONAL RESEARCH & OPINION

Better care in Alzheimer's disease?The number of managed-care plans for the treatment

of patients with Alzheimer's disease (AD) is likely toincrease in the US, according to a new Datamonitor report.

The report states that the care for patients with ADin the US remains poor. Therefore, new initiatives,involving health maintenance organisations, Medicareand pharmaceutical companies, have been launched inan attempt to improve the quality of care in the managedcare setting. Improvements in the management ofADmay also generate cost savings, suggests Datanwnitor.

Recent and future drugs used in the treatment ofpatients with AD will be supported at launch bydisease management (DM) programmes that will beintroduced simultaneously. Such DM progranunes havealready been developed and implemented in line withthe marketing of some medications: e.g. 'The FamilyCare System' was developed by Warner-Lambert inassociation with tacrine, and TriAD, although not aproduct-specific programme, was launched by Eisaiand Pfizer in association with donepezil.Datarnonitor. Pharmaceutical companies, HMOs and disease associationstake new initiatives to improve the management of Alzheimer's disease.Media Release: [5 pages], 17 Nov 1997 lIOO629Ol9

1173-55Q319710140-000111$01.oo0 Adlsinternationaillmlted 1997. All rlghts .....rved PharmacoEconomics & Outcomes News 29 Nov 1997 No. 140